The outlook of companies tied to Sildenafil's legacy presents a intricate investment landscape. While the initial success generated substantial profits , generic alternatives here have significantly diminished sales . Investing in related pharmaceutical firms now requires a thorough assessment of intellectual property safeguards, evolving patient s